we implemented a restructuring plan in each of the first , third and fourth quarters of fiscal year 2018 consisting of workforce reductions principally intended to realign resources to emphasize growth initiatives ( the `` q1 2018 plan `` , `` q3 2018 plan `` and `` q4 2018 plan `` , respectively ) . we implemented a restructuring plan in each of the fourth and third quarters of fiscal year 2017 consisting of workforce reductions principally intended to realign resources to emphasize growth initiatives ( the `` q4 2017 plan and `` q3 2017 plan `` , respectively ) . we implemented a restructuring plan in the first quarter of fiscal year 2017 consisting of workforce reductions and the closure of excess facility space principally intended to focus resources on higher growth end markets ( the `` q1 2017 plan `` ) . we implemented a restructuring plan in the third quarter of fiscal year 2016 consisting of workforce reductions principally intended to focus resources on higher growth product lines ( the `` q3 2016 plan `` ) . we implemented a restructuring plan in the second quarter of fiscal year 2016 consisting of workforce reductions principally intended to focus resources on higher growth end markets ( the `` q2 2016 plan `` ) . all other previous restructuring plans were workforce reductions or the closure of excess facility space principally intended to integrate our businesses in order to realign 27 operations , reduce costs , achieve operational efficiencies and shift resources into geographic regions and end markets that are more consistent with our growth strategy ( the `` previous plans `` ) . the following table summarizes the number of employees reduced , the initial restructuring or contract termination charges by operating segment , and the dates by which payments were substantially completed , or the expected dates by which payments will be substantially completed , for restructuring actions implemented during fiscal years 2018 , 2017 and 2016 in continuing operations : replace_table_token_5_th we expect to make payments under the previous plans for remaining residual lease obligations , with terms varying in length , through fiscal year 2022 . we also have terminated various contractual commitments in connection with certain disposal activities and have recorded charges , to the extent applicable , for the costs of terminating these contracts before the end of their terms and the costs that will continue to be incurred for the remaining terms without economic benefit to us . we recorded additional pre-tax charges of $ 5.0 million , $ 3.6 million and $ 0.1 million in the discovery & analytical solutions segment during fiscal years 2018 , 2017 and 2016 , respectively , and $ 0.5 million during fiscal year 2017 in the diagnostics segment as a result of these contract terminations . 28 at december 30 , 2018 , we had $ 6.2 million recorded for accrued restructuring and contract termination charges , of which $ 4.8 million was recorded in short-term accrued restructuring and $ 1.4 million was recorded in long-term liabilities . at december 31 , 2017 , we had $ 14.0 million recorded for accrued restructuring and contract termination charges , of which $ 8.8 million was recorded in short-term accrued restructuring , $ 2.3 million was recorded in long-term liabilities and $ 2.9 million was recorded in other reserves . the following table summarizes our restructuring accrual balances and related activity by restructuring plan , as well as contract termination accrual balances and related activity , during fiscal years 2018 , 2017 and 2016 in continuing operations : replace_table_token_6_th ( 1 ) during fiscal year 2018 , we recognized pre-tax restructuring reversals of $ 0.2 million each in the discovery & analytical solutions and diagnostics segments , related to lower than expected costs associated with workforce reductions for the q4 2017 plan . ( 2 ) during fiscal year 2018 , we recognized pre-tax restructuring reversals of $ 0.8 million in the discovery & analytical solutions segment and $ 0.4 million in the diagnostics segment , related to lower than expected costs associated with workforce reductions for the q3 2017 plan . ( 3 ) during fiscal year 2018 , we recognized pre-tax restructuring reversals of $ 1.0 million in the discovery & analytical solutions segment , related to lower than expected costs associated with workforce reductions for the q1 2017 plan . 29 interest and other expense , net interest and other expense , net , consisted of the following : replace_table_token_7_th 2018 compared to 2017 . interest and other expense , net , for fiscal year 2018 was an expense of $ 66.2 million , as compared to income of $ 1.1 million for fiscal year 2017 , an increase of $ 67.3 million . the increase in interest and other expense , net , in fiscal year 2018 as compared to fiscal year 2017 was largely due to an increase in other expense , net of $ 56.0 million resulting from a one-time non-recurring net foreign exchange gain of $ 36.5 million in fiscal year 2017 related to remeasurement and settlement of euroimmun pre-acquisition hedges , combined with an increase in pension-related expenses of $ 20.7 million in fiscal year 2018 as compared to fiscal year 2017. interest expense increased by $ 23.0 million in fiscal year 2018 as compared to fiscal year 2017 primarily due to a higher outstanding total debt balance , beginning in the fourth quarter of fiscal year 2017 , related to financing for the euroimmun acquisition . story_separator_special_tag when the discontinued operations represented a strategic shift that will have a major effect on our operations and financial statements , we accounted for these businesses as discontinued operations and accordingly , have presented the results of operations and related cash flows as discontinued operations . any business deemed to be a discontinued operation prior to the adoption of accounting standards update 2014-08 , reporting discontinued operations and disclosures of disposals of components of an entity , continues to be reported as a discontinued operation , and the results of operations and related cash flows are presented as discontinued operations for all periods presented . any remaining assets and liabilities of these businesses have been presented separately , and are reflected within assets and liabilities from discontinued operations in the accompanying consolidated balance sheets as of december 30 , 2018 and december 31 , 2017 . 31 we recorded the following pre-tax gains and losses , which have been reported as a net gain or loss on disposition of discontinued operations during the three fiscal years included below : replace_table_token_9_th on may 1 , 2017 ( the `` closing date `` ) , we completed the sale of our medical imaging business to varex imaging corporation ( `` varex `` ) pursuant to the terms of the master purchase and sale agreement , dated december 21 , 2016 ( the “ agreement ” ) , by and between us and varian medical systems , inc. ( `` varian `` ) and the subsequent assignment and assumption agreement , dated january 27 , 2017 , between varian and varex , pursuant to which varian assigned its rights under the agreement to varex . on the closing date , we received consideration of approximately $ 277.4 million for the sale of the medical imaging business . during fiscal year 2017 , we paid varex $ 4.2 million to settle a post-closing working capital adjustment . during fiscal year 2017 , we recorded a pre-tax gain of $ 179.6 million and income tax expense of $ 43.1 million related to the sale of the medical imaging business in discontinued operations and dispositions . the corresponding tax liability was recorded within the other tax liabilities in the consolidated balance sheet , and we expect to utilize tax attributes to minimize the tax liability . following the closing , we provided certain customary transitional services during a period of up to 12 months . commercial transactions between the parties following the closing of the transaction were not significant . during the third quarter of fiscal year 2018 , we completed the sale of substantially all of the assets and liabilities related to our multispectral imaging business for aggregate consideration of $ 37.3 million , recognizing a pre-tax gain of $ 13.0 million . the pre-tax gain is included in interest and other expense , net in the consolidated statement of operations . the multispectral imaging business was a component of our discovery & analytical solutions segment . the divestiture of the multispectral imaging business has not been classified as a discontinued operation in this form 10-k because the disposition does not represent a strategic shift that will have a major effect on our operations and financial statements . during fiscal year 2017 , we sold suzhou perkinelmer medical laboratory co. , ltd. for aggregate consideration of $ 2.3 million , recognizing a pre-tax loss of $ 1.1 million . the pre-tax loss recognized in fiscal year 2017 is included in interest and other expense , net in the consolidated statement of operations . suzhou perkinelmer medical laboratory co. , ltd. was a component of our diagnostics segment . the divestiture of suzhou perkinelmer medical laboratory co. , ltd. has not been classified as a discontinued operation in this form 10-k because the disposition does not represent a strategic shift that will have a major effect on our operations and financial statements . during fiscal year 2016 , we sold perkinelmer labs , inc. for cash consideration of $ 20.0 million , recognizing a pre-tax gain of $ 7.1 million . the sale generated a capital loss for tax purposes of $ 7.3 million , which resulted in an income tax benefit of $ 2.5 million that was recognized as a discrete benefit during the second quarter of 2016. during fiscal year 2017 , we recognized an additional pre-tax gain of $ 1.1 million relating to the earn-out consideration received from the buyer . perkinelmer labs , inc. was a component of our diagnostics segment . the pre-tax gain recognized in fiscal years 2017 and 2016 is included in interest and other expense , net in the consolidated statements of operations . the divestiture of perkinelmer labs , inc. has not been classified as a discontinued operation in this form 10-k because the disposition does not represent a strategic shift that will have a major effect on our operations and financial statements . in august 1999 , we sold the assets of our technical service business . we recorded a pre-tax gain of $ 1.8 million in fiscal year 2016 for a contingency related to this business . this was recognized as a gain on disposition of discontinued operations before income taxes . the summary pre-tax operating results of the discontinued operations were as follows during the three fiscal years ended : 32 replace_table_token_10_th we recorded a ( benefit from ) provision for income taxes of $ ( 1.3 ) million , $ 44.5 million and $ 4.3 million on discontinued operations and dispositions in fiscal years 2018 , 2017 and 2016 . business combinations acquisitions in fiscal year 2018 during fiscal year 2018 , we completed the acquisition of four businesses for aggregate consideration of $ 106.0 million . the excess of the purchase price over the fair value of the acquired businesses ' net assets represents cost and revenue synergies specific to us , as well as non-capitalizable intangible assets , such as the

net cash provided by continuing operations was $ 311.2 million for fiscal year 2018 , as compared to net cash provided by continuing operations of $ 292.2 million for fiscal year 2017 , an increase of $ 19.1 million . the cash provided by operating activities for fiscal year 2018 was principally a result of income from continuing operations of $ 237.5 37 million , and non-cash charges , including depreciation and amortization of $ 180.6 million , stock based compensation expense of $ 28.8 million , change in fair value of contingent consideration of $ 14.6 million , a non-cash expense of $ 11.9 million related to our postretirement benefit plans , including the mark-to-market adjustment in the fourth quarter of fiscal year 2018 , restructuring and contract termination charges , net , of $ 11.1 million , and amortization of deferred debt issuance costs and accretion of discounts of $ 3.3 million . these amounts were partially offset by a net increase in working capital of $ 115.8 million , deferred tax benefit of $ 51.1 million , a net increase of $ 3.7 million in accrued expenses , other assets and liabilities and other items , a gain from disposition of businesses and assets , net of $ 12.8 million , and a gain on sale of investments , net of $ 0.6 million . the change in accrued expenses , other assets and liabilities and other items increase d cash provided by operating activities by $ 3.7 million for fiscal year 2018 , primarily related to the timing of payments for pension , taxes , restructuring , royalties and salary and benefits .


 Write a concise suspicious activity report of the following text delimited by triple backquotes. Return your response as a formal report which covers the key points highlighting the location,dates,entity names and account holder information in chronological order of the text.
     ```net cash provided by continuing operations was $ 311.2 million for fiscal year 2018 , as compared to net cash provided by continuing operations of $ 292.2 million for fiscal year 2017 , an increase of $ 19.1 million . the cash provided by operating activities for fiscal year 2018 was principally a result of income from continuing operations of $ 237.5 37 million , and non-cash charges , including depreciation and amortization of $ 180.6 million , stock based compensation expense of $ 28.8 million , change in fair value of contingent consideration of $ 14.6 million , a non-cash expense of $ 11.9 million related to our postretirement benefit plans , including the mark-to-market adjustment in the fourth quarter of fiscal year 2018 , restructuring and contract termination charges , net , of $ 11.1 million , and amortization of deferred debt issuance costs and accretion of discounts of $ 3.3 million . these amounts were partially offset by a net increase in working capital of $ 115.8 million , deferred tax benefit of $ 51.1 million , a net increase of $ 3.7 million in accrued expenses , other assets and liabilities and other items , a gain from disposition of businesses and assets , net of $ 12.8 million , and a gain on sale of investments , net of $ 0.6 million . the change in accrued expenses , other assets and liabilities and other items increase d cash provided by operating activities by $ 3.7 million for fiscal year 2018 , primarily related to the timing of payments for pension , taxes , restructuring , royalties and salary and benefits .
```    
 Suspicious Activity Report : we implemented a restructuring plan in each of the first , third and fourth quarters of fiscal year 2018 consisting of workforce reductions principally intended to realign resources to emphasize growth initiatives ( the `` q1 2018 plan `` , `` q3 2018 plan `` and `` q4 2018 plan `` , respectively ) . we implemented a restructuring plan in each of the fourth and third quarters of fiscal year 2017 consisting of workforce reductions principally intended to realign resources to emphasize growth initiatives ( the `` q4 2017 plan and `` q3 2017 plan `` , respectively ) . we implemented a restructuring plan in the first quarter of fiscal year 2017 consisting of workforce reductions and the closure of excess facility space principally intended to focus resources on higher growth end markets ( the `` q1 2017 plan `` ) . we implemented a restructuring plan in the third quarter of fiscal year 2016 consisting of workforce reductions principally intended to focus resources on higher growth product lines ( the `` q3 2016 plan `` ) . we implemented a restructuring plan in the second quarter of fiscal year 2016 consisting of workforce reductions principally intended to focus resources on higher growth end markets ( the `` q2 2016 plan `` ) . all other previous restructuring plans were workforce reductions or the closure of excess facility space principally intended to integrate our businesses in order to realign 27 operations , reduce costs , achieve operational efficiencies and shift resources into geographic regions and end markets that are more consistent with our growth strategy ( the `` previous plans `` ) . the following table summarizes the number of employees reduced , the initial restructuring or contract termination charges by operating segment , and the dates by which payments were substantially completed , or the expected dates by which payments will be substantially completed , for restructuring actions implemented during fiscal years 2018 , 2017 and 2016 in continuing operations : replace_table_token_5_th we expect to make payments under the previous plans for remaining residual lease obligations , with terms varying in length , through fiscal year 2022 . we also have terminated various contractual commitments in connection with certain disposal activities and have recorded charges , to the extent applicable , for the costs of terminating these contracts before the end of their terms and the costs that will continue to be incurred for the remaining terms without economic benefit to us . we recorded additional pre-tax charges of $ 5.0 million , $ 3.6 million and $ 0.1 million in the discovery & analytical solutions segment during fiscal years 2018 , 2017 and 2016 , respectively , and $ 0.5 million during fiscal year 2017 in the diagnostics segment as a result of these contract terminations . 28 at december 30 , 2018 , we had $ 6.2 million recorded for accrued restructuring and contract termination charges , of which $ 4.8 million was recorded in short-term accrued restructuring and $ 1.4 million was recorded in long-term liabilities . at december 31 , 2017 , we had $ 14.0 million recorded for accrued restructuring and contract termination charges , of which $ 8.8 million was recorded in short-term accrued restructuring , $ 2.3 million was recorded in long-term liabilities and $ 2.9 million was recorded in other reserves . the following table summarizes our restructuring accrual balances and related activity by restructuring plan , as well as contract termination accrual balances and related activity , during fiscal years 2018 , 2017 and 2016 in continuing operations : replace_table_token_6_th ( 1 ) during fiscal year 2018 , we recognized pre-tax restructuring reversals of $ 0.2 million each in the discovery & analytical solutions and diagnostics segments , related to lower than expected costs associated with workforce reductions for the q4 2017 plan . ( 2 ) during fiscal year 2018 , we recognized pre-tax restructuring reversals of $ 0.8 million in the discovery & analytical solutions segment and $ 0.4 million in the diagnostics segment , related to lower than expected costs associated with workforce reductions for the q3 2017 plan . ( 3 ) during fiscal year 2018 , we recognized pre-tax restructuring reversals of $ 1.0 million in the discovery & analytical solutions segment , related to lower than expected costs associated with workforce reductions for the q1 2017 plan . 29 interest and other expense , net interest and other expense , net , consisted of the following : replace_table_token_7_th 2018 compared to 2017 . interest and other expense , net , for fiscal year 2018 was an expense of $ 66.2 million , as compared to income of $ 1.1 million for fiscal year 2017 , an increase of $ 67.3 million . the increase in interest and other expense , net , in fiscal year 2018 as compared to fiscal year 2017 was largely due to an increase in other expense , net of $ 56.0 million resulting from a one-time non-recurring net foreign exchange gain of $ 36.5 million in fiscal year 2017 related to remeasurement and settlement of euroimmun pre-acquisition hedges , combined with an increase in pension-related expenses of $ 20.7 million in fiscal year 2018 as compared to fiscal year 2017. interest expense increased by $ 23.0 million in fiscal year 2018 as compared to fiscal year 2017 primarily due to a higher outstanding total debt balance , beginning in the fourth quarter of fiscal year 2017 , related to financing for the euroimmun acquisition . story_separator_special_tag when the discontinued operations represented a strategic shift that will have a major effect on our operations and financial statements , we accounted for these businesses as discontinued operations and accordingly , have presented the results of operations and related cash flows as discontinued operations . any business deemed to be a discontinued operation prior to the adoption of accounting standards update 2014-08 , reporting discontinued operations and disclosures of disposals of components of an entity , continues to be reported as a discontinued operation , and the results of operations and related cash flows are presented as discontinued operations for all periods presented . any remaining assets and liabilities of these businesses have been presented separately , and are reflected within assets and liabilities from discontinued operations in the accompanying consolidated balance sheets as of december 30 , 2018 and december 31 , 2017 . 31 we recorded the following pre-tax gains and losses , which have been reported as a net gain or loss on disposition of discontinued operations during the three fiscal years included below : replace_table_token_9_th on may 1 , 2017 ( the `` closing date `` ) , we completed the sale of our medical imaging business to varex imaging corporation ( `` varex `` ) pursuant to the terms of the master purchase and sale agreement , dated december 21 , 2016 ( the “ agreement ” ) , by and between us and varian medical systems , inc. ( `` varian `` ) and the subsequent assignment and assumption agreement , dated january 27 , 2017 , between varian and varex , pursuant to which varian assigned its rights under the agreement to varex . on the closing date , we received consideration of approximately $ 277.4 million for the sale of the medical imaging business . during fiscal year 2017 , we paid varex $ 4.2 million to settle a post-closing working capital adjustment . during fiscal year 2017 , we recorded a pre-tax gain of $ 179.6 million and income tax expense of $ 43.1 million related to the sale of the medical imaging business in discontinued operations and dispositions . the corresponding tax liability was recorded within the other tax liabilities in the consolidated balance sheet , and we expect to utilize tax attributes to minimize the tax liability . following the closing , we provided certain customary transitional services during a period of up to 12 months . commercial transactions between the parties following the closing of the transaction were not significant . during the third quarter of fiscal year 2018 , we completed the sale of substantially all of the assets and liabilities related to our multispectral imaging business for aggregate consideration of $ 37.3 million , recognizing a pre-tax gain of $ 13.0 million . the pre-tax gain is included in interest and other expense , net in the consolidated statement of operations . the multispectral imaging business was a component of our discovery & analytical solutions segment . the divestiture of the multispectral imaging business has not been classified as a discontinued operation in this form 10-k because the disposition does not represent a strategic shift that will have a major effect on our operations and financial statements . during fiscal year 2017 , we sold suzhou perkinelmer medical laboratory co. , ltd. for aggregate consideration of $ 2.3 million , recognizing a pre-tax loss of $ 1.1 million . the pre-tax loss recognized in fiscal year 2017 is included in interest and other expense , net in the consolidated statement of operations . suzhou perkinelmer medical laboratory co. , ltd. was a component of our diagnostics segment . the divestiture of suzhou perkinelmer medical laboratory co. , ltd. has not been classified as a discontinued operation in this form 10-k because the disposition does not represent a strategic shift that will have a major effect on our operations and financial statements . during fiscal year 2016 , we sold perkinelmer labs , inc. for cash consideration of $ 20.0 million , recognizing a pre-tax gain of $ 7.1 million . the sale generated a capital loss for tax purposes of $ 7.3 million , which resulted in an income tax benefit of $ 2.5 million that was recognized as a discrete benefit during the second quarter of 2016. during fiscal year 2017 , we recognized an additional pre-tax gain of $ 1.1 million relating to the earn-out consideration received from the buyer . perkinelmer labs , inc. was a component of our diagnostics segment . the pre-tax gain recognized in fiscal years 2017 and 2016 is included in interest and other expense , net in the consolidated statements of operations . the divestiture of perkinelmer labs , inc. has not been classified as a discontinued operation in this form 10-k because the disposition does not represent a strategic shift that will have a major effect on our operations and financial statements . in august 1999 , we sold the assets of our technical service business . we recorded a pre-tax gain of $ 1.8 million in fiscal year 2016 for a contingency related to this business . this was recognized as a gain on disposition of discontinued operations before income taxes . the summary pre-tax operating results of the discontinued operations were as follows during the three fiscal years ended : 32 replace_table_token_10_th we recorded a ( benefit from ) provision for income taxes of $ ( 1.3 ) million , $ 44.5 million and $ 4.3 million on discontinued operations and dispositions in fiscal years 2018 , 2017 and 2016 . business combinations acquisitions in fiscal year 2018 during fiscal year 2018 , we completed the acquisition of four businesses for aggregate consideration of $ 106.0 million . the excess of the purchase price over the fair value of the acquired businesses ' net assets represents cost and revenue synergies specific to us , as well as non-capitalizable intangible assets , such as the

